Key result
Acute cerebral infarction is linked to higher plasma CaM and lower miR-26b expression.
Why the study?
The regulatory mechanisms of calmodulin (CaM) expression at the gene level in acute cerebral infarction (ACI) are limited, and the role of miR-26b as a potential regulator of CALM1 mRNA during ACI is unclear.
Does miR-26b regulate CaM expression and correlate with disease severity in acute cerebral infarction?
Case-Control
Does miR-26b regulate CaM expression and correlate with disease severity in acute cerebral infarction?
CaM may serve as a novel blood biomarker for acute cerebral infarction, with its expression regulated post-transcriptionally by miR-26b.
Answers are grounded in this paper and cite their sources.
miR-26b and CaM expression may aid ACI prognosis; leaves open mechanistic or therapeutic roles pending prospective validation.
BACKGROUND: Calcium overload plays an important role in ischemia/reperfusion injury during ischemic brain damage and is mediated by calmodulin (CaM). However, the understanding of the regulatory mechanisms of CaM expression at the gene level is limited. The expression levels of miR-26b change significantly during ACI, and bioinformatic analyses predict that miR-26b would be a potential regulator of calmodulin (CALM1) mRNA. This study aimed to determine the expression of miR-26b and CaM in the plasma of patients with ACI and investigate the impact of miR-26b on CALM1 expression. METHODS: CaM and miR-26b expression analyses from the plasma of patients with ACI and normal controls were performed using ELISA and qRT-PCR, respectively. Correlations between CaM, miR-26b, and NIHSS scores were analyzed. Then, miR-26b mimics and inhibitors were transfected into HUVE cell lines via lipofectamine. CALM1 mRNA expression in HUVECs was detected by RT-PCR, and the protein levels were detected by Western blot. RESULTS: Plasma CaM expression in patients with ACI was significantly higher when compared with normal controls, and miR-26b expression was significantly lower. The plasma levels of CaM and miR-26b were correlated with the NIHSS scores in ACI patients. miR-26b modulated CALM1 in vitro. The transfected miR-26b mimic and inhibitor significantly altered the expression of CALM1/CAM at the mRNA and protein levels in cultured HUVECs. CONCLUSIONS: CaM might be a potential novel blood marker in patients with ACI. miR-26b targeted CALM1 and affected the expression of CaM at the post-transcriptional level, which likely contributed to the progression of ACI brain injury.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2015) conducted a case-control in Acute cerebral infarction. Acute cerebral infarction vs. Normal controls was evaluated on Plasma CaM and miR-26b expression levels. Plasma CaM expression was significantly higher and miR-26b expression was significantly lower in patients with acute cerebral infarction compared with normal controls.
Synapse has enriched 10 related papers. Consider them for comparative context: